Europe Anthrax Treatment Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143108
- Pages: 225
-
Format:
Short Description
Europe Anthrax Treatment Market, By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others), End User (Government Organization, Hospitals, Academic and Research Institutes, and Others), Country (Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg and Rest of Europe )Industry Trends and Forecast to 2029.
Market Definition:
Anthrax is caused by a bacterium called Bacillus anthracis (B. anthracis). It is primarily a disease of livestock that become infected by ingesting spores found in soil. Humans usually become infected with anthrax by handling products of infected animals such as leather or wool or by inhaling anthrax spores from infected animal products. They can also become infected by eating undercooked meat from infected animals. Anthrax is not known to be spread person-to-person.
Three clinical forms of anthrax infection exist. Cutaneous anthrax is the most common, constituting over 95% of reported cases. An estimated 2000 cases of cutaneous anthrax occur worldwide annually and result from the entry of spores through skin abrasions.
The differential diagnosis of anthrax includes depending on the clinical features, relevant specimens include PCR, gram stain, and cultures, from blood, pleural fluid, site of ulceration, cerebrospinal fluid, and stool. A number of available techniques are available. Most assays are based on detecting the entire organism, organism antigens, or organism nucleic acid through one of the following techniques: culture-based conventional methods; immunological detection; nucleic-acid-based assays; ligand-based detection; and biosensors.
Market Segmentation:
Europe anthrax treatment market is categorized based on type, route of administration and end user.
On the basis of type, the Europe anthrax treatment market is segmented into cutaneous anthrax, pulmonary anthrax and intestinal anthrax
On the basis of route of administration, Europe anthrax treatment market is segmented into oral, parenteral and others
On the basis of end user, Europe anthrax treatment market is segmented into government organization, hospitals, academic and research institutes, and others
Market Players
The key market players for Europe anthrax treatment market are listed below:
Alembic Pharmaceuticals
Sun Pharmaceutical Industries Ltd.
Zydus Group
Bayer AG
Pfizer Inc.
EMERGENT
Sanofi, Porton Biopharma
Lupin
Soligenix
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
ARISTO Pharmaceuticals Private Limited
INDOCO REMEDIES LTD.
DEINOVE
TABLE OF CONTENTS
1 INTRODUCTION 74
1.1 OBJECTIVES OF THE STUDY 74
1.2 MARKET DEFINITION 74
1.3 OVERVIEW OF THE EUROPE ANTHRAX TREATMENT MARKET 74
1.4 LIMITATIONS 76
1.5 MARKETS COVERED 76
2 MARKET SEGMENTATION 79
2.1 MARKETS COVERED 79
2.2 GEOGRAPHICAL SCOPE 80
2.3 YEARS CONSIDERED FOR THE STUDY 81
2.4 CURRENCY AND PRICING 81
2.5 DBMR TRIPOD DATA VALIDATION MODEL 82
2.6 MULTIVARIATE MODELLING 85
2.7 PRODUCT SEGMENT LIFELINE CURVE 85
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 86
2.9 DBMR MARKET POSITION GRID 87
2.10 MARKET APPLICATION COVERAGE GRID 88
2.11 VENDOR SHARE ANALYSIS 89
2.12 SECONDARY SOURCES 90
2.13 ASSUMPTIONS 90
3 EXECUTIVE SUMMARY 91
4 PREMIUM INSIGHTS 95
4.1 PESTEL ANALYSIS 96
4.2 PORTERS FIVE FORCES 97
4.3 DEMOGRAPHIC TRENDS- 98
4.4 EPIDEMIOLOGY AND DEMOGRAPHICS- 100
4.4.1 INCIDENCE 100
4.4.2 DEVELOPED COUNTRIES- 100
4.4.3 DEVELOPING COUNTRIES- 100
4.5 PATIENT ENROLMENT STRATEGIES- 102
4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION- 106
4.7 CURRENT STATE OF ANTHRAX VACCINES 108
4.8 EUROPE ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018. 112
4.9 EUROPE ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION- 113
5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEARS ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANYS PIPELINE FOR ANTHRAX TREATMENT. 117
6 EUROPE ANTHRAX TREATMENT MARKET: REGULATIONS 119
7 MARKET OVERVIEW 123
7.1 DRIVERS 125
7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION 125
7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX 125
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE 126
7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS 126
7.2 RESTRAINTS 127
7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT 127
7.2.2 FALSE DATA INTERPRETATION 128
7.3 OPPORTUNITIES 128
7.3.1 RISING PRODUCT LAUNCHES 128
7.3.2 RISING GOVERNMENT INITIATIVES 129
7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM 129
7.4 CHALLENGES 130
7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION 130
7.4.2 LACK OF SKILLED PROFESSIONALS 130
8 EUROPE ANTHRAX TREATMENT MARKET, BY TYPE 132
8.1 OVERVIEW 133
8.2 CUTANEOUS ANTHRAX 136
8.2.1 ANTIBIOTICS 137
8.2.1.1 BY DRUGS 137
8.2.1.1.1 CIPROFLOXACIN 138
8.2.1.1.2 LEVOFLOXACIN 138
8.2.1.1.3 DOXYCYCLINE 138
8.2.1.1.4 AMPICILLIN 138
8.2.1.1.5 OTHERS 138
8.2.1.2 BY PRODUCT TYPES 138
8.2.1.2.1 GENERICS 138
8.2.1.2.2 BRANDED 138
8.2.1.2.2.1 CIPRO 139
8.2.1.2.2.2 LEVO 139
8.2.1.2.2.3 DOXY 139
8.2.1.2.2.4 AMPICI 139
8.2.1.2.2.5 OTHERS 139
8.2.2 ANTITOXINS 140
8.2.2.1 RAXIBACUMAB 140
8.2.2.2 OBILTOXAXIMAB (ANTHIM) 140
8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 140
8.2.2.4 OTHERS 140
8.2.3 VACCINES 141
8.2.3.1 RAXIBACUMAB 141
8.2.4 SURGERY 141
8.3 PULMONARY ANTHRAX 141
8.3.1 ANTIBIOTICS 142
8.3.1.1 BY DRUGS 143
8.3.1.1.1 CIPROFLOXACIN 143
8.3.1.1.2 LEVOFLOXACIN 143
8.3.1.1.3 DOXYCYCLINE 143
8.3.1.1.4 AMPICILLIN 143
8.3.1.1.5 OTHERS 143
8.3.1.2 BY PRODUCT TYPES 144
8.3.1.2.1 GENERICS 144
8.3.1.2.2 BRANDED 144
8.3.1.2.2.1 CIPRO 144
8.3.1.2.2.2 LEVO 145
8.3.1.2.2.3 DOXY 145
8.3.1.2.2.4 AMPICI 145
8.3.1.2.2.5 OTHERS 145
8.3.2 ANTITOXINS 145
8.3.2.1 RAXIBACUMAB 145
8.3.2.2 OBILTOXAXIMAB (ANTHIM) 145
8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 145
8.3.2.4 OTHERS 146
8.3.3 VACCINES 146
8.3.3.1 RAXIBACUMAB 146
8.3.3.2 SURGERY 146
8.4 INTESTINAL ANTHRAX 146
8.4.1 ANTIBIOTICS 148
8.4.1.1 BY DRUGS 148
8.4.1.1.1 CIPROFLOXACIN 148
8.4.1.1.2 LEVOFLOXACIN 148
8.4.1.1.3 DOXYCYCLINE 148
8.4.1.1.4 AMPICILLIN 149
8.4.1.1.5 OTHERS 149
8.4.1.2 BY PRODUCT TYPES 149
8.4.1.2.1 GENERICS 149
8.4.1.2.2 BRANDED 149
8.4.1.2.2.1 CIPRO 150
8.4.1.2.2.2 LEVO 150
8.4.1.2.2.3 DOXY 150
8.4.1.2.2.4 AMPICI 150
8.4.1.2.2.5 OTHERS 150
8.4.2 ANTITOXINS 151
8.4.2.1 RAXIBACUMAB 151
8.4.2.2 OBILTOXAXIMAB (ANTHIM) 151
8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 151
8.4.2.4 OTHERS 151
8.4.3 VACCINES 152
8.4.3.1 RAXIBACUMAB 152
8.4.3.2 SURGERY 152
9 EUROPE ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 153
9.1 OVERVIEW 154
9.2 PARENTERAL 157
9.3 ORAL 157
9.4 OTHERS 158
10 EUROPE ANTHRAX TREATMENT MARKET, BY END USER 159
10.1 OVERVIEW 160
10.2 GOVERNMENT ORGANIZATION 163
10.3 HOSPITALS 163
10.4 ACADEMIC AND RESEARCH 164
10.5 OTHERS 166
11 EUROPE VIRTUAL REALITY MARKET, BY GEOGRAPHY 167
11.1 EUROPE 168
11.1.1 GERMANY 184
11.1.2 FRANCE 195
11.1.3 U.K. 205
11.1.4 ITALY 216
11.1.5 RUSSIA 227
11.1.6 SPAIN 237
11.1.7 TURKEY 247
11.1.8 NETHERLANDS 257
11.1.9 SWITZERLAND 268
11.1.10 BELGIUM 279
11.1.11 REST OF EUROPE 290
12 EUROPE ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE 291
12.1 COMPANY SHARE ANALYSIS: EUROPE 291
13 SWOT ANALYSIS 292
14 COMPANY PROFILE 293
14.1 BAYER AG 293
14.1.1 COMPANY SNAPSHOT 293
14.1.2 REVENUE ANALYSIS 293
14.1.3 COMPANY SHARE ANALYSIS 294
14.1.4 PRODUCT PORTFOLIO 294
14.1.5 RECENT DEVELOPMENTS 294
14.2 PFIZER INC. 295
14.2.1 COMPANY SNAPSHOT 295
14.2.2 REVENUE ANALYSIS 295
14.2.3 COMPANY SHARE ANALYSIS 296
14.2.4 PRODUCT PORTFOLIO 296
14.2.5 RECENT DEVELOPMENTS 296
14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD 297
14.3.1 COMPANY SNAPSHOT 297
14.3.2 REVENUE ANALYSIS 297
14.3.3 COMPANY SHARE ANALYSIS 298
14.3.4 PRODUCT PORTFOLIO 298
14.3.5 RECENT DEVELOPMENT 298
14.4 SANOFI 299
14.4.1 COMPANY SNAPSHOT 299
14.4.2 REVENUE ANALYSIS 299
14.4.3 COMPANY SHARE ANALYSIS 300
14.4.4 PRODUCT PORTFOLIO 300
14.4.5 RECENT DEVELOPMENTS 300
14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED. 301
14.5.1 COMPANY SNAPSHOT 301
14.5.2 REVENUE ANALYSIS 301
14.5.3 PRODUCT PORTFOLIO 302
14.5.4 RECENT DEVELOPMENT 302
14.6 ALEMBIC PHARMACEUTICALS LIMITED 303
14.6.1 COMPANY SNAPSHOT 303
14.6.2 PRODUCT PORTFOLIO 303
14.6.3 RECENT DEVELOPMENTS 303
14.7 ALTIMMUNE 304
14.7.1 COMPANY SNAPSHOT 304
14.7.2 REVENUE ANALYSIS 304
14.7.3 PRODUCT PORTFOLIO 305
14.7.4 RECENT DEVELOPMENTS 305
14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED 306
14.8.1 COMPANY SNAPSHOT 306
14.8.2 PRODUCT PORTFOLIO 306
14.8.3 RECENT DEVELOPMENTS 306
14.9 BLUEWILLOW BIOLOGICS. 307
14.9.1 COMPANY SNAPSHOT 307
14.9.2 PRODUCT PORTFOLIO 307
14.9.3 RECENT DEVELOPMENTS 307
14.10 DEINOVE 308
14.10.1 COMPANY SNAPSHOT 308
14.10.2 REVENUE ANALYSIS 308
14.10.3 PRODUCT PORTFOLIO 309
14.10.4 RECENT DEVELOPMENTS 309
14.11 EMERGENT 310
14.11.1 COMPANY SNAPSHOT 310
14.11.2 REVENUE ANALYSIS 310
14.11.3 PRODUCT PORTFOLIO 311
14.11.4 RECENT DEVELOPMENTS 311
14.12 ELUSYS THERAPEUTICS INC. 312
14.12.1 COMPANY SNAPSHOT 312
14.12.2 PRODUCT PORTFOLIO 312
14.12.3 RECENT DEVELOPMENTS 312
14.13 GC BIOPHARMA CORP. 313
14.13.1 COMPANY SNAPSHOT 313
14.13.2 REVENUE ANALYSIS 313
14.13.3 PRODUCT PORTFOLIO 314
14.13.4 RECENT DEVELOPMENTS 314
14.14 INDOCO REMEDIES LTD. 315
14.14.1 COMPANY SNAPSHOT 315
14.14.2 REVENUE ANALYSIS 315
14.14.3 PRODUCT PORTFOLIO 316
14.14.4 RECENT DEVELOPMENTS 316
14.15 INTEGRATED BIOTHERAPEUTICS, INC. 317
14.15.1 COMPANY SNAPSHOT 317
14.15.2 PRODUCT PORTFOLIO 317
14.15.3 RECENT DEVELOPMENTS 317
14.16 LUPIN. 318
14.16.1 COMPANY SNAPSHOT 318
14.16.2 REVENUE ANALYSIS 318
14.16.3 PRODUCT PORTFOLIO 319
14.16.4 RECENT DEVELOPMENTS 319
14.17 PARATEK PHARMACEUTICALS, INC. 320
14.17.1 COMPANY SNAPSHOT 320
14.17.2 REVENUE ANALYSIS 320
14.17.3 PRODUCT PORTFOLIO 321
14.17.4 RECENT DEVELOPMENTS 321
14.18 PORTON BIOPHARMA 322
14.18.1 COMPANY SNAPSHOT 322
14.18.2 PRODUCT PORTFOLIO 322
14.18.3 RECENT DEVELOPMENTS 322
14.19 SOLIGENIX 323
14.19.1 COMPANY SNAPSHOT 323
14.19.2 REVENUE ANALYSIS 323
14.19.3 PRODUCT PORTFOLIO 324
14.19.4 RECENT DEVELOPMENTS 324
14.20 SUN PHARMACEUTICAL INDUSTRIES LTD. 325
14.20.1 COMPANY SNAPSHOT 325
14.20.2 REVENUE ANALYSIS 325
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
